Jasper Therapeutics (JSPR) POS AM 24 Mar 22 Prospectus update (post-effective amendment) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2021
Document Information Line Items
Entity Registrant Name	Jasper Therapeutics, Inc.
Document Type	POS AM
Amendment Flag	true
Amendment Description	This Post-Effective Amendment No. 1 (“Post-Effective Amendment No. 1”) to the Registration Statement on Form S-1 (File No. 333-260306) (the “Registration Statement”), as originally declared effective by the Securities and Exchange Commission (the “SEC”) on October 26, 2021, is being filed to include information contained in the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 18, 2022 and to update certain other information in the Registration Statement.The information included in this filing amends the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment No. 1. All applicable registration fees were paid at the time of the original filing of the Registration Statement on October 18, 2021.
Entity Central Index Key	0001788028
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 84,701	$ 19,838
Other receivables		600
Prepaid expenses and other current assets	3,130	247
Total current assets	87,831	20,685
Property and equipment, net	3,686	693
Operating lease right-of-use assets	1,147	1,336
Restricted cash	345	345
Other non-current assets	645	298
Total assets	93,654	23,357
Current liabilities:
Accounts payable	3,919	1,417
Current portion of operating lease liabilities	505
Accrued expenses and other current liabilities	3,596	2,595
Total current liabilities	8,020	4,012
Derivative tranche liability		8,158
Non-current portion of operating lease liabilities	2,380	1,624
Common stock warrant liability	7,350
Earnout liability	5,743
Other non-current liabilities	643	853
Total liabilities	24,136	14,647
Commitments and contingencies (Note 9)
Redeemable convertible preferred stock: $0.0001 par value — none and 19,522,771 shares authorized at December 31, 2021 and 2020, respectively; none and 15,480,195 shares issued and outstanding at December 31, 2021 and 2020, respectively; liquidation value $41,165 at December 31, 2020		43,840
Stockholders’ equity (deficit)
Preferred stock: $0.0001 par value — 10,000,000 shares and none authorized at December 31, 2021 and 2020, respectively; none issued and outstanding at December 31, 2021 and 2020
Common stock: $0.0001 par value — 492,000,000 and 50,218,502 shares authorized at December 31, 2021 and 2020, respectively; 37,855,114 and 2,770,702 shares issued and outstanding at December 31, 2021 and 2020, respectively	4	1
Additional paid-in capital	136,964	1,682
Accumulated deficit	(67,450)	(36,813)
Total stockholders’ equity (deficit)	69,518	(35,130)
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)	$ 93,654	$ 23,357

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Redeemable convertible preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Redeemable convertible preferred stock, shares authorized		19,522,771
Redeemable convertible preferred stock, shares issued		15,480,195
Redeemable convertible preferred stock, shares outstanding		15,480,195
Redeemable convertible preferred stock, liquidation value (in Dollars)		$ 41,165
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	492,000,000	50,218,502
Common stock, shares issued	37,855,114	2,770,702
Common stock, shares outstanding	37,855,114	2,770,702

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses
Research and development	$ 25,421	$ 15,883
General and administrative	11,412	4,800
Total operating expenses	36,833	20,683
Loss from operations	(36,833)	(20,683)
Change in fair value of earnout liability	9,277
Change in fair value of derivative liability	(3,501)	(10,875)
Change in fair value of common stock warrant liability	500
Other expense, net	(80)	(111)
Total other income (expense), net	6,196	(10,986)
Net loss and comprehensive loss	$ (30,637)	$ (31,669)
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	$ (2.69)	$ (5.17)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in Shares)	11,393,753	6,125,897

Consolidated Statements of Rede

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($) $ in Thousands		Preferred Stock	Common Stock		Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019		$ 25,836	$ 1		$ 409	$ (5,144)	$ (4,734)
Balance (in Shares) at Dec. 31, 2019	[1]	11,255,430	2,695,264
Issuance of common stock upon exercise of stock options					53		53
Issuance of common stock upon exercise of stock options (in Shares)			75,438	[1]
Issuance of Series A-1 redeemable convertible preferred stock for cash		$ 11,234
Issuance of Series A-1 redeemable convertible preferred stock for cash (in Shares)	[1]	4,224,765
Settlement of the redeemable convertible preferred stock tranche liability		$ 6,770
Vesting of founders’ restricted stock					10		10
Stock-based compensation expense					1,210		1,210
Net loss						(31,669)	(31,669)
Balance at Dec. 31, 2020		$ 43,840	$ 1		1,682	(36,813)	(35,130)
Balance (in Shares) at Dec. 31, 2020	[1]	15,480,195	2,770,702
Issuance of common stock upon exercise of stock options					235		235
Issuance of common stock upon exercise of stock options (in Shares)			323,740	[1]
Issuance of common stock upon exercise of common stock warrants					1		1
Issuance of common stock upon exercise of common stock warrants (in Shares)	[1]		110
Issuance of Series A-1 redeemable convertible preferred stock for cash		$ 10,750
Issuance of Series A-1 redeemable convertible preferred stock for cash (in Shares)	[1]	4,042,565
Settlement of the redeemable convertible preferred stock tranche liability		$ 11,659
Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization (Note 3)		$ (66,249)	$ 2		66,247		66,249
Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization (Note 3) (in Shares)	[1]	(19,522,760)	21,722,661
Issuance of common stock upon the Reverse Recapitalization and PIPE Financing, net of issuance costs			$ 1		67,741		67,742
Issuance of common stock upon the Reverse Recapitalization and PIPE Financing, net of issuance costs (in Shares)	[1]		13,037,901
Vesting of founders’ restricted stock					10		10
Stock-based compensation expense					1,048		1,048
Net loss						(30,637)	(30,637)
Balance at Dec. 31, 2021			$ 4		$ 136,964	$ (67,450)	$ 69,518
Balance (in Shares) at Dec. 31, 2021			37,855,114	[1]
[1]	The shares of the Company’s common and redeemable convertible preferred stock, prior to the Reverse Recapitalization (as defined in Note 1) have been retroactively restated to reflect the exchange ratio of 0.282378, except for 100 shares of Series A -2

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (30,637)	$ (31,669)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense	377
Non-cash lease expense	189	21
Stock-based compensation expense	1,048	1,210
Change in fair value of derivative liability	3,501	10,875
Change in fair value of common stock warrant liability	(500)
Change in fair value of earnout liability	(9,277)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,212)	(247)
Other receivables	600
Other non-current assets	(347)	(250)
Accounts payable	2,938	358
Accrued expenses and other current liabilities	959	1,225
Operating lease liability	(117)	10
Other non-current liabilities	(200)	200
Net cash used in operating activities	(33,678)	(18,267)
Cash flows used in investing activities
Purchases of property and equipment	(2,428)
Net cash used in investing activities	(2,428)
Cash flows from financing activities
Net proceeds from Reverse Recapitalization and PIPE Financing (Note 3)	95,271
Payment of Reverse Recapitalization related expenses	(5,288)
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	10,750	11,234
Proceeds from exercise of common stock options	235	53
Proceeds from exercise of common stock warrants	1
Net cash provided by financing activities	100,969	11,287
Net increase (decrease) in cash, cash equivalents and restricted cash	64,863	(6,980)
Cash, cash equivalents and restricted cash at beginning of the year	20,183	27,163
Cash, cash equivalents and restricted cash at end of the year	85,046	20,183
Supplemental and non-cash items reconciliations:
Accounts payable and accrued expenses for purchases of property and equipment		436
Right-of-use asset obtained in exchange for lease liabilities		1,357
Non-cash leasehold improvements	1,378	256
Vesting of founders’ restricted stock	10	10
Conversion of redeemable convertible preferred stock into common stock in connection with Reverse Recapitalization	(66,249)
Deferred issuance costs reclassified to additional paid in capital	5,288
Net liabilities assumed upon the closing of Reverse Recapitalization	(7,222)
Recognition of earnout liability	15,020
Recognition (settlement) of derivative tranche liability	(11,659)	(6,770)
Letter of credit issued in connection with lease recognition		$ 345

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS Description of Business Jasper Therapeutics, Inc. (“Jasper” or the “Company”), formerly known as Amplitude Healthcare Acquisition Corporation (“AMHC”), is a clinical -stage On September 24, 2021 (the “Closing Date”), the Company consummated the previously announced business combination (the “Business Combination” or “Reverse Recapitalization” for accounting purposes) pursuant to the terms of the Business Combination Agreement, dated as of May 5, 2021 (the “BCA”), by and among AMHC, Ample Merger Sub, Inc., a then -wholly-owned -Business -owned In addition, concurrently with the execution of the BCA, certain investors (the “PIPE Investors”) entered into Subscription Agreements with AMHC whereby such investors subscribed for the purchase of an aggregate of 10,000,000 Please refer to Note 3, “Reverse Recapitalization”, for further details of the Business Combination. Liquidity and Need for Additional Capital The Company has incurred significant losses and negative cash flows from operations since its inception. During the years ended December 31, 2021 and 2020, the Company incurred net losses of $30.6 million and $31.7 million, respectively. During the years ended December 31, 2021 and 2020, the Company had negative operating cash flows of $33.7 million and $18.3 million, respectively. As of December 31, 2021, the Company had an accumulated deficit of $67.5 million. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support the Company’s cost structure. The Company’s cash and cash equivalents of $84.7 million as of December 31, 2021 are not sufficient for the Company to continue as a going concern for at least one year from the issuance date of these consolidated financial statements. Additional funds are necessary to maintain current operations and to continue research and development activities. The Company’s management plans to monitor expenses and raise additional capital through a combination of public and private equity, debt financings, strategic alliances, and licensing arrangements. The Company’s ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts, needed, the Company could be required to delay, scale back, or abandon some or all of its development programs and other operations, which could materially harm the Company’s business, financial condition and results of operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Coronavirus Pandemic In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (“COVID -19 -from-home -essential -to-work While the Company’s operations to date have not been significantly impacted by the COVID -19 -19 -19 -19 -19

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and regulations of the U.S. Securities and Exchange Commission for financial reporting. The accompanying financial statements are consolidated for the year ended December 31, 2021 and include the accounts of Jasper Therapeutics, Inc. (i.e., formerly known as AMHC) and its wholly -owned All historical share data and per -share -2 -2 Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to the valuation of common and redeemable convertible preferred stock before the Reverse Recapitalization, the determination of the incremental borrowing rate used for operating lease liabilities, valuation of derivative liability, valuation of earnout liability and the measurement of stock -based Cash, Cash Equivalents, and Restricted Cash The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total amount shown in the consolidated statements of cash flows (in thousands): December 31, 2021 2020 Cash and cash equivalents $ 84,701 $ 19,838 Restricted cash 345 345 Total cash, cash equivalents and restricted cash $ 85,046 $ 20,183 Cash and cash equivalents consist of checking account and investments in money market funds with an original maturity of three months or less at the time of purchase. The recorded carrying amount of cash and cash equivalents approximates their fair value. Restricted cash relates to the letter of credit secured in conjunction with the operating lease (Note 9). Concentrations of Credit Risk and Other Risks and Uncertainties The Company’s cash and cash equivalents are maintained with financial institutions in the United States of America. Management believes that these financial institutions are financially sound. The Company has not experienced any losses on its cash and cash equivalents. The Company is subject to risks common to companies in the development stage, including, but not limited to, development and regulatory approval of new product candidates, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product plans. To achieve profitable operations, the Company must successfully develop and obtain requisite regulatory approvals for, manufacture, and market its product candidates. There can be no assurance that any such product candidate can be developed and approved or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product will be successfully marketed. These factors could have a material adverse effect on the Company’s future financial results. Products developed by the Company require approval from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s future products will receive the necessary clearances. If the Company were denied such clearances or such clearances were delayed, it could have a materially adverse impact on the Company. Deferred Transaction Costs The Company capitalized qualified legal, accounting, and other direct costs related to the Business Combination, which were deferred until completion of the Business Combination. Upon the completion of the Business Combination, all deferred costs were recorded as a reduction to additional paid -in Property and Equipment, Net Property and equipment, net is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight -line Impairment of Long-Lived Assets The Company reviews its long -lived -lived -lived -lived Leases The Company determines whether an arrangement is or contains a lease at the inception of the arrangement and whether such a lease is classified as a financing lease or operating lease at the commencement date of the lease. Leases with a term greater than one year are recognized on the balance sheet as operating right -of-use -current -of-use -term -of-use -of-use -of-use The Company considers the lease term to be the noncancelable period that it has the right to use the underlying asset, together with any periods where it is reasonably certain it will exercise an option to extend (or not terminate) the lease. Periods covered by an option to extend (or not terminate) the lease in which the exercise of the option is controlled by the lessor are included in the lease term. Rent expense for operating leases is recognized on a straight -line -lease -lease The Company has no finance leases as of December 31, 2021 and 2020. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities, derivative tranche liability, common stock warrant liability, contingent earnout liability and other non -current -based -term Redeemable Convertible Preferred Stock The Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs and bifurcated derivative tranche liability, which was bifurcated as it was concluded to be a freestanding financial instrument liability. The redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company’s control such as a merger, acquisition or sale of all or substantially all of the Company’s assets (each, a deemed liquidation event), the redeemable convertible preferred stock became redeemable at the option of the holders of at least 55% of the then outstanding shares. The Company did not adjust the carrying values of the redeemable convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock was not probable of occurring. Common Stock Warrant Liability The Company has outstanding warrants to purchase 4,999,883 -voting -voting -current Contingent Earnout Liability At the closing of the Business Combination, the Company recognized the earnout liability related to the Sponsor Support Agreement, dated May 5, 2021 and amended on September 24, 2021, by and among the Company, Amplitude Healthcare Holdings LLC (the “Sponsor”) and Old Jasper (as amended, the “Sponsor Support Agreement”), pursuant to which 1,050,000 -40 Derivative Tranche Liability The Company determined that its obligation to issue additional shares of redeemable convertible preferred stock upon the occurrence of certain events, including a number of patients enrolled in the clinical trials, or the consent of the Company’s Board of Directors (the “Board”), represented a freestanding financial instrument. The instrument was classified as a liability on the consolidated balance sheets and was subject to re -measurement Accrued Research and Development Expenses The Company has entered into various agreements with outsourced vendors, CMOs and CROs. The Company makes estimates of accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred. Research and Development The Company expenses research and development (“R&D”) expenses as incurred. R&D expenses consist primarily of personnel -related -related -based -related General and Administrative General and administrative expenses include compensation, employee benefits and stock -based Stock-Based Compensation The Company measures its stock -based -employees -Scholes -pricing -free -based -line -based Income Taxes The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction -by-jurisdiction Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. To date, there have been no interest or penalties recorded in relation to unrecognized tax benefits. Foreign Currency Transactions Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re -measured -measured Comprehensive loss Comprehensive loss represents all changes in stockholders’ equity (deficit) except those resulting from distributions to stockholders. There have been no items qualifying as other comprehensive income (loss) during the years ended December 31, 2021 and 2020, and therefore, the Company’s comprehensive loss was the same as its reported net loss. Net Loss per Share Attributable to Common Stockholders Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted -average -average Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two -class obligation to share in the Company’s losses. As such, the net loss is attributed entirely to common stockholders. For the years ended December 31, 2021 and 2020, the diluted net loss per share of common stock was the same as basic net loss per share of common stock, as the impact of potentially dilutive securities was antidilutive to the net loss per share. The Earnout Shares and common stock subject to restricted stock awards are contingently issuable shares and are not included in the diluted net loss per share calculation until contingencies are resolved. Segment Reporting The Company has determined it operates as a single operating and reportable segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources. All long -lived Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2019 -12

Reverse Recapitalization

Reverse Recapitalization	12 Months Ended
	Dec. 31, 2021
Reverse Recapitalization [Abstract]
REVERSE RECAPITALIZATION	NOTE 3. REVERSE RECAPITALIZATION On the Closing Date, the Company consummated the Business Combination in accordance with the BCA. Merger Sub merged with Old Jasper, with Old Jasper as the surviving company and as a wholly -owned Prior to the closing of the Business Combination, holders of 9,262,099 In accordance with the Subscription Agreements between AMHC and the PIPE Investors, AMHC issued to the PIPE Investors 10,000,000 In accordance with the BCA, at the closing of the Business Combination, each share of Old Jasper common stock and Old Jasper redeemable convertible preferred stock outstanding immediately prior to the closing was automatically cancelled, extinguished and converted into the number of shares of the Company’s common stock or, in certain circumstances, the Company’s non -voting -for-0 -2 In connection with the Business Combination, immediately prior to the closing, (i) the Sponsor forfeited 200,000 Immediately after giving effect to the Reverse Recapitalization, there were 36,520,288 -voting The Business Combination is accounted for as a reverse recapitalization under U.S. GAAP. This determination is primarily based on Old Jasper’s stockholders comprising a relative majority of the voting power of the Company and having the ability to nominate the members of the Board, Old Jasper’s operations prior to the acquisition comprising the only ongoing operations of the Company, and Old Jasper’s senior management comprising a majority of the senior management of the Company. Under this method of accounting, AMHC is treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the consolidated financial statements of the Company represent a continuation of the financial statements of Old Jasper with the Business Combination being treated as the equivalent of the Company issuing stock for the net assets of AMHC, accompanied by a reverse recapitalization. The net assets of AMHC are stated at historical costs, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are presented as those of Old Jasper. In connection with the Business Combination, the Company received $95.3 million in net cash proceeds. This amount was comprised of $5.5 million of cash held in AMHC’s trust account from its initial public offering (after payment of redemptions and public offering expenses paid at the closing of the Business Combination) and $100.0 million of cash received by AMHC in connection with the PIPE Financing, net of AMHC’s transaction costs and placement agents’ fees of $9.0 million and operating expense payments of $1.2 million. The Company incurred $5.3 million of transaction costs, consisting of legal, professional, and banking fees, which were recorded as a reduction to additional paid -in At the Closing Date, the Company also recognized AMHC’s net assets of $0.6 million, the fair value of common stock warrant liability of $7.9 million, and the fair value of earnout liability of $15.0 million. The number of shares of common stock issued and outstanding immediately following the consummation of the Business Combination was: Number of Common stock of AMHC outstanding prior to the Business Combination 12,500,000 Less: shares forfeited by the Sponsor (200,000 ) Less: redemption of AMHC shares (9,262,099 ) Common stock of AMHC 3,037,901 Shares issued in the PIPE Financing 10,000,000 Business Combination and PIPE Financing shares 13,037,901 Old Jasper shares 24,778,409 Total shares of common stock immediately after the Business Combination 37,816,310

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 4. FAIR VALUE MEASUREMENTS The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market -based -tier • • • In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value and is a Level 1 financial instrument under the fair value hierarchy. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like -kind Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques and at least one significant model assumption or input is unobservable. Level 3 liabilities that are measured at fair value on a recurring basis included the derivative tranche liability, which was extinguished in February 2021, and earnout liability, which was recognized in connection with the Business Combination. During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at estimated fair value using Level 3 inputs. There were no transfers within the hierarchy during the years ended December 31, 2021 and 2020. The following tables set forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands): December 31, 2021 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 83,701 $ — $ — $ 83,701 Total fair value of assets $ 83,701 $ — $ — $ 83,701 Financial liabilities Common stock warrant liability $ 7,350 $ — $ — $ 7,350 Earnout liability — — 5,743 5,743 Total fair value of financial liabilities $ 7,350 $ — $ 5,743 $ 13,093 December 31, 2020 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 18,778 $ — $ — $ 18,778 Total fair value of assets $ 18,778 $ — $ — $ 18,778 Financial liabilities Derivative liability $ — $ — $ 8,158 $ 8,158 Total fair value of financial liabilities $ — $ — $ 8,158 $ 8,158 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities (in thousands): Derivative Earnout Fair Value as of January 1, 2020 $ 4,053 $ — Initial fair value of derivative instrument — — Change in the fair value included in other expense 10,875 — Settlement of obligation (6,770 ) — Fair Value as of December 31, 2020 $ 8,158 $ — Fair Value as of January 1, 2021 $ 8,158 $ — Initial fair value of earnout liability — 15,020 Change in the fair value included in other expense (income) 3,501 (9,277 ) Settlement of obligation (11,659 ) — Fair Value as of December 31, 2021 $ — $ 5,743 The derivative tranche liability was measured using the option pricing method by estimating the value using the Black -Scholes -Scholes -free The estimated fair value of the earnout liability is determined using Monte Carlo simulation model, which uses a distribution of potential outcomes on a monthly basis over the earnout period prioritizing the most reliable information available. The assumptions utilized in the calculation are based on the achievement of certain stock price milestones, including the current Company’s common stock price, expected volatility, risk -free The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements classified in Level 3 of the fair value hierarchy at December 31, 2021: Fair value Valuation Significant unobservalble input Earnout liability $ 5,743 Monte Carlo Simulation Common stock price $ 7.85 Expected term (in years) 2.73 Expected volatility 74.00 % Risk -free 0.90 % The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements classified in Level 3 of the fair value hierarchy at December 31, 2020: Fair value Valuation Significant unobservalble input Derivative tranche liability $ 8,158 Black -Scholes Expected term (in years) 0.16 Expected volatility 47.02 % Risk -free 0.08 % Expected dividend yield 0.00 %

Consolidated Balance Sheet Comp

Consolidated Balance Sheet Components	12 Months Ended
	Dec. 31, 2021
Condensed Financial Information Disclosure [Abstract]
CONSOLIDATED BALANCE SHEET COMPONENTS	NOTE 5. CONSOLIDATED BALANCE SHEET COMPONENTS Prepaid expenses and other current assets The following table summarizes the details of prepaid expenses and other current assets as of the dates set forth below (in thousands): December 31, 2021 2020 Prepaid insurance $ 2,074 $ — Payroll tax credit receivable 548 — Research and development prepaid expenses 139 177 Other receivables 150 — Other prepaid expenses 171 43 Rent deposit 27 27 Other current assets 21 — Total $ 3,130 $ 247 Property and equipment, net The following table summarizes the details of property and equipment, net as of the dates set forth below (in thousands): December 31, 2021 2020 Leasehold improvements $ 2,056 $ 256 Lab equipment 1,569 437 Office furniture & fixtures 208 — Computer equipment 140 — Capitalized software 90 — 4,063 693 Less: accumulated depreciation and amortization (377 ) — Property and equipment, net $ 3,686 $ 693 Depreciation and amortization expense for the year ended December 31, 2021 was $0.4 million. No depreciation or amortization expense was recognized during the year ended December 31, 2020. Accrued expenses and other current liabilities The following table summarizes the details of accrued expenses and other current liabilities as of the dates set forth below (in thousands): December 31, 2021 2020 Research and development accrued expenses $ 1,660 $ 1,263 Accrued employee and related compensation expenses 1,151 783 License option liability, current 200 400 Other 585 149 Total $ 3,596 $ 2,595 Other non-current liabilities The following table summarizes the details of other non -current December 31, 2021 2020 CIRM grant liability $ 600 $ 600 Accrued tax liability 24 — Restricted stock liability 19 53 License option liability, non-current — 200 Total $ 643 $ 853

Cirm Grant

Cirm Grant	12 Months Ended
	Dec. 31, 2021
Cirm Grant Disclosure [Abstract]
CIRM GRANT	NOTE 6. CIRM GRANT In November 2020, California Institute for Regenerative Medicine (“CIRM”) awarded the Company $2.3 million in support of the research project related to a monoclonal antibody that depletes blood stem cells and enables chemotherapy -free -funded -fund -funding -funded -funded -month -term -term

Significant Agreements

Significant Agreements	12 Months Ended
	Dec. 31, 2021
Significant Agreements [Abstract]
SIGNIFICANT AGREEMENTS	NOTE 7. SIGNIFICANT AGREEMENTS Amgen License Agreement On November 21, 2019, the Company entered into a license agreement with Amgen (the “Amgen License Agreement”), pursuant to which the Company obtained an exclusive, sublicensable license for certain patents, data, and non -data -how Under the ISRA, the Company was provided an option to negotiate a definitive license with Stanford for rights to certain Stanford intellectual property related to the study of JSP191 in exchange for an option exercise fee of $1.0 million, payable over a two -year As consideration for the rights granted to the Company under the license agreement with Amgen, Old Jasper issued Amgen 100 -2 The Amgen License Agreement terminates on a country -by-country th -by-country -exclusive After the closing of the Business Combination, Amgen owns more than 5% of the Company’s outstanding common stock and is considered to be a related party. Stanford License Agreement In March 2021, the Company entered into the Stanford License Agreement, following the exercise of the Option in June 2020. The Company received a worldwide, exclusive license with a right to sublicense for JSP191 in the field of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated. Stanford transferred to the Company certain know -how The Company will pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and second year, $35,000 for each third and fourth year, and $50,000 at each anniversary thereafter ending upon the first commercial sale. The Company is also obligated to pay late -stage -digit The Stanford License Agreement expires on a country -by-country -to-expire -day

Derivative Financial Instrument

Derivative Financial Instruments	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS	NOTE 8. DERIVATIVE FINANCIAL INSTRUMENTS Derivative Tranche Liability The Company determined that the obligation to issue additional shares of Series A -1 On September 3, 2020, Old Jasper’s board of directors amended the Series A -1 The first milestone was re -measured -1 -measured -1 February 26, Series A-1 redeemable convertible preferred stock value $ 1.57 Purchase price $ 0.75 Expected term (in years) — Expected volatility 0.00 % Risk-free interest rate 0.00 % The Company recorded $3.5 million and $10.9 million loss from the remeasurement of the derivative tranche liability in its consolidated statements of operations and comprehensive loss during the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the derivative tranche liability was fully settled. Common Stock Warrants The Common Stock Warrants are traded on the Nasdaq Capital Market and may only be exercised for a whole number of shares. The Common Stock Warrants became exercisable on October 24, 2021 and expire on September 24, 2026, unless early redeemed or if the Company extends the exercise period. The fair value of $7.9 million of Common Stock Warrants was recognized as a liability on September 24, 2021, the Closing Date, based on the closing market price. 110 Common Stock Warrants have been exercised as of December 31, 2021. The Company recognized a gain of $0.5 million for the year ended December 31, 2021, classified within change in fair value of common stock warrant liability in the consolidated statements of operations. The Common Stock Warrants’ fair value was $7.4 million as of December 31, 2021. Contingent Earnout Liability Upon the closing of the Business Combination and pursuant to the Sponsor Support Agreement, the Sponsor agreed to place the Earnout Shares into escrow, which will be released as follows: (a) 250,000 Earnout Shares will be released if, during the period from and after September 24, 2021 until the September 24, 2024 (the “Earnout Period”), over any twenty trading days within any thirty -day -weighted The Earnout Shares placed in escrow are legally issued and outstanding shares that participate in voting and dividends. The Earnout Shares (along with related escrowed dividends, if any) will be forfeited and not released from escrow at the end of the Earnout Period unless the triggering events described above are achieved during the Earnout Period. Upon the closing of the Business Combination, the contingent obligation to release the Earnout Shares was accounted for as a liability classified financial instrument upon their initial recognition because the triggering events that determine the number of shares required to be released from escrow include events that were not solely indexed to the common stock of the Company. The earnout liability is remeasured each reporting period with changes in fair value recognized in earnings. At the closing of the Business Combination, the estimated fair value of the earnout liability was $15.0 million based on a Monte Carlo simulation model. Assumptions used in the valuation are described below: September 24, Common stock value $ 15.12 Expected term (in years) 3.00 Expected volatility 75.00 % Risk-free interest rate 0.55 % At December 31, 2021, the estimated fair value of the earnout liability was $5.7 million based on a Monte Carlo simulation model. Assumptions used in the valuation as of December 31, 2021 are described in Note 4. No triggering event occurred as of December 31, 2021. The Company recognized a gain of $9.3 million for the year ended December 31, 2021, classified within change in fair value of earnout liability in the consolidated statements of operations and comprehensive loss.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9. COMMITMENTS AND CONTINGENCIES Operating Leases In August 2020, the Company entered into an operating lease for laboratory and office space in Redwood City, California, that expires in August 2026. In January 2022, this lease was amended to add additional rented space (Note 17). In conjunction with signing the lease, the Company secured a letter of credit in favor of the lessor in the amount of $0.3 million. The funds related to this letter of credit are presented as restricted cash on the Company’s consolidated balance sheets. The lease agreement includes an escalation clause for increased base rent and a renewal provision allowing the Company to extend this lease for an additional 60 months at the prevailing rental rate, which the Company is not reasonably certain to exercise. In addition to base rent, the Company will pay its share of operating expenses and taxes. To complete certain leasehold improvements, the lessor agreed to provide the Company a tenant improvement allowance of $1.2 million as well as an option to take an additional allowance of $0.4 million to be repaid over the lease term at an interest rate of 9% per annum, which the Company exercised. The Company recognized $1.6 million and $0.3 million in leasehold improvements covered by these allowances as of December 31, 2021 and 2020, respectively. In accordance with the lease agreement, the lessor managed and supervised the construction of the improvements. In exchange for these services, the Company paid the lessor a fee equal to 5% of total construction costs. The leasehold improvements constructed are presented under property and equipment on the Company’s consolidated balance sheets and will be amortized on a straight -line In addition to the construction management and supervision fee noted above, the Company pays variable costs related to its share of operating expenses and taxes. These variable costs are recorded as lease expense as incurred and presented as operating expenses in the consolidated statements of operations and comprehensive loss. The components of lease costs, which were included in the Company’s consolidated statements of operations and comprehensive loss, are as follows (in thousands): Year ended December 31, 2021 2020 Lease cost Operating lease cost* $ 479 $ 45 Short-term lease cost 326 301 Total lease cost $ 805 $ 346 * Includes $90,000 and $13,000 of variable lease cost related to the construction management and supervision fee during the years ended December 31, 2021 and 2020, respectively, and $50,000 variable costs related to operating expenses or taxes during the year ended December 31, 2021. No variable costs related to operating expenses or taxes have been incurred as of December 31, 2020. Supplemental information related to the Company’s operating leases is as follows: Year ended December 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities $ 301 $ — Weighted average remaining lease term (years) 4.6 5.4 Weighted average discount rate 8.00 % 8.00 % The following table summarizes a maturity analysis of the Company’s operating lease liabilities showing the aggregate lease payments as of December 31, 2021 (in thousands): Amount Year ending December 31, 2022 $ 713 2023 735 2024 757 2025 779 2026 461 Total undiscounted lease payments 3,445 Less imputed interest (560 ) Total discounted lease payments 2,885 Less current portion of lease liability (505 ) Noncurrent portion of lease liability $ 2,380 Stanford Sponsored Research Agreement Effective September 2020, the Company entered into a sponsored research agreement with Stanford for a research program related to the treatment of Fanconi Anemia patients in Bone Marrow Failure requiring allogeneic transplant with non -sibling As consideration for the services performed by Stanford under this sponsored research agreement, the Company will pay Stanford a total of $0.9 million over approximately 3 years upon the achievement of development and clinical milestones, including FDA filings and patients’ enrollment. As of December 31, 2020, the Company had accrued $0.3 million related to the achievement of the first milestone under this agreement, which was paid in February 2021. The second and the third milestones are based on the progress of the clinical trials and will be recognized when achieved. License agreements In March 2021, the Company entered into the Stanford License Agreement (Note 7), pursuant to which the Company is required to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and second year, $35,000 for each third and fourth year, and $50,000 at each anniversary thereafter ending upon the first commercial sale. The Company is also obligated to pay late -stage -digit Legal proceedings The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2021 and 2020, and, to the best of its knowledge, no material legal proceedings are currently pending. Guarantees and Indemnifications In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of December 31, 2021 and 2020, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2021
Redeemable Convertible Preferred Stock Details [Abstract]
REDEEMABLE CONVERTIBLE PREFERRED STOCK	NOTE 10: REDEEMABLE CONVERTIBLE PREFERRED STOCK On September 24, 2021, upon the closing of the Business Combination, all shares of the outstanding redeemable convertible preferred stock were cancelled and exchanged for 21,722,661 -voting Redeemable convertible preferred stock as of December 31, 2020 consisted of the following (in thousands, except share data): December 31, 2020 Shares Authorized Shares Aggregate Net Series A-1 redeemable convertible preferred stock 19,522,671 15,480,095 $ 41,165 $ 42,978 Series A-2 redeemable convertible preferred stock 100 100 — 862 Total redeemable convertible preferred stock 19,522,771 15,480,195 $ 41,165 $ 43,840 The significant rights and obligations of the redeemable convertible preferred stock were as follows: Dividends The holders of Series A -1 The holders of Series A -2 -kit -kit The preferred dividends were not cumulative. No dividends had been declared or paid as of December 31, 2021 and 2020. Voting The holders of each share of Series A -1 -1 -1 -converted -2 Election of Directors The holders of Series A -1 -1 Conversion Rights Each share of Series A -1 would have been issued upon conversion of the shares in excess of 9.9% in the form of Class B common stock. The initial conversion price per share for Series A -1 -2 Each share of Series A -1 -1 -1 Upon Old Jasper’s initial public offering, each share of Series A -2 -2 -kit -kit Liquidation Preference In the event of liquidation, dissolution or winding up of Old Jasper, including deemed liquidation, the holders of the Series A -1 -2 After the payment to the holders of Series A -1 -2 -2 -kit -kit After the payment to the holders of Series A -2 -1 If the assets of Old Jasper legally available for distribution to the holders of a given Series of redeemable convertible preferred stock were insufficient to permit the payment to such holders of the full amounts of a given Series, then the assets of Old Jasper would have been distributed on a pro rata basis among the holders of such Series of redeemable convertible preferred stock in proportion to the full amounts they would otherwise be entitled to receive pursuant to their liquidation preference. Following the above payments, the remaining assets of Old Jasper, if any, would have been distributed ratably among the holders of common stock and Series A -1 -1 -1 the applicable original issue price and (ii) the amount would have received if all shares of Series A -1 Redemption The redeemable convertible preferred stock was recorded in mezzanine equity because while it was not mandatorily redeemable, it would have become redeemable at the option of the preferred stockholders upon the occurrence of certain deemed liquidation events that were considered not solely within the Company’s control.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2021
Common Stock [Abstract]
COMMON STOCK	NOTE 11: COMMON STOCK On September 24, 2021, upon the closing of the Business Combination, the Company issued (1) 13,037,901 -voting The Company is authorized to issue 490,000,000 -voting -voting Holders of the voting common stock and the non -voting -voting -voting -voting As of December 31, 2021 and 2020, the Company had common stock reserved for future issuance as follows: December 31, 2021 2020 Redeemable convertible preferred stock — 15,480,195 Outstanding and issued common stock options 2,660,383 2,983,574 Common stock warrants 4,999,883 — Shares available for grant under 2019 Equity Incentive Plan — 430,893 Shares available for grant under 2021 Equity Incentive Plan 4,422,480 — Shares available for grant under 2021 Employee Stock Purchase Plan 550,000 — Total shares of common stock reserved 12,632,746 18,894,662 Founders’ Common Stock In March 2018, Old Jasper issued 2,259,024 The Company accounts for issued shares as stock -based -based -based -based

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	NOTE 12. STOCK-BASED COMPENSATION On September 23, 2021, the 2021 Equity Incentive Plan (“2021 Plan”) and the 2021 Employee Stock Purchase Plan (“2021 ESPP”) became effective upon the prior approval of Old Jasper’s board of directors and stockholders. As of December 31, 2021, 4,422,480 and 550,000 Under the 2021 Plan, the Company can grant ISOs, NSOs, RSAs, stock appreciation rights, restricted stock units, performance awards and other awards to employees, directors and consultants. Under the 2021 ESPP, the Company can grant purchase rights to employees to purchase shares of common stock at a purchase price which equal to 85% of the fair market value of common stock on the offering date or on the exercise date, whichever is lower. No awards have been granted under the 2021 Plan and no shares have been issued under the ESPP as of December 31, 2021. No further awards will be granted under the 2019 Equity Incentive Plan (“2019 Plan”), and options to purchase 2,660,383 Under the 2019 Plan and the 2021 Plan, options are granted at an exercise price of not less than 100% of the fair market value of the common stock on the date of grant. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. Options become exercisable and expire as specified in the award agreement, provided that the term of options may not exceed 10 years from the date of grant (5 years for the individuals holding more than 10% of the voting rights of all classes of stock). Stock option agreements may provide for accelerated exercisability in the event of an optionee’s death, disability, retirement or other events. Vesting conditions determined by the administrator of the applicable plan may apply to stock options and may include continued service, performance and/or other conditions. Generally, stock options vest over a four -year Stock Option Activity The following table summarizes the activity under the 2021 Plan and the 2019 Plan for the year ended December 31, 2021: Option Outstanding Weighted Aggregate Shares Number of Weighted Balance, January 1, 2021 430,893 2,983,574 $ 0.71 9.52 $ 5,599,957 Shares available for grant cancelled (407,864 ) Shares authorized 4,400,000 Options granted (145,753 ) 145,753 $ 2.59 Options exercised — (323,740 ) $ 0.72 Options cancelled/forfeited 145,204 (145,204 ) $ 0.72 Balance, December 31, 2021 4,422,480 2,660,383 $ 0.81 8.54 $ 18,731,908 Vested and expected to vest, December 31, 2021 2,660,383 $ 0.81 8.54 $ 18,731,908 Exercisable 1,568,645 $ 0.71 8.74 $ 13,642,291 Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in -the-money The total fair value of options that vested during the years ended December 31, 2021 and 2020 was $1.4 million and $0.8 million, respectively. The weighted -average Future stock -based -average Stock-Based Compensation Expense The following table presents stock -based -employees Year Ended December 31, 2021 2020 Research and development $ 612 $ 488 General and administrative 436 722 Total $ 1,048 $ 1,210 Valuation of Stock Options The grant date fair value of employee stock options was estimated using a Black -Scholes -pricing -average Year Ended December 31, 2021 2020 Expected term (in years) 5.29 – 6.08 5.00 – 6.06 Expected volatility 75.27% – 75.79% 74.27% – 75.61% Risk-free interest rate 0.65% – 0.80% 0.27% – 0.45% Expected dividend yield — — The determination of the fair value of stock options on the date of grant using a Black -Scholes -pricing Fair Value of Common Stock Prior to the Business Combination, the grant date fair value of Old Jasper’s common stock was determined by its board of directors with the assistance of management and an independent third -party -free -Held-Company After the Business Combination, the Company uses its closing market price as of the grant date to estimate an option’s grant date fair value. Expected Term The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid -point Expected Volatility The Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company does not have any trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Risk-Free Interest Rate The risk -free Expected Dividend Yield The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	NOTE 13. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): Year Ended December 31, 2021 2020 Numerator: Net loss attributable to common stockholders $ (30,637 ) $ (31,669 ) Denominator: Weighted average common shares outstanding 12,363,677 2,697,181 Less: Weighted-average unvested restricted shares (685,129 ) (967,363 ) Less: Weighted-average shares subject to earnout (284,795 ) — Weighted average shares used to compute basic and diluted net loss per share 11,393,753 1,729,818 Net loss per share attributable to common stockholders – basic and diluted $ (2.69 ) $ (18.31 ) As a result of the Business Combination, the Company has retroactively adjusted the weighted -average The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows: December 31, 2021 2020 Common stock warrants 4,999,883 — Outstanding and issued common stock options 2,660,383 2,983,574 Unvested restricted common stock 541,225 823,603 Convertible preferred stock — 15,480,195 Total 8,201,491 19,287,372

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 14. INCOME TAXES During the years ended December 31, 2021 and 2020, the Company did not incur any tax expense or benefit as the Company operated with taxable losses and provided a full valuation allowance. The provision for income taxes differs from the amount computed by applying the federal statutory income tax rate to loss before taxes as follows (in thousands): Year Ended December 31, 2021 2020 Federal tax benefit at statutory rate $ (6,433 ) $ (6,651 ) State taxes (1,729 ) (1,757 ) Change in fair value of derivative 735 2,284 Change in fair value of warrant liability (105 ) — Change in fair value of earnout liability (1,948 ) — Non-deductible expenses 633 231 Research and development credits (1,095 ) (298 ) Change in valuation allowance 10,095 6,191 Other (153 ) — Provision for income taxes $ — $ — Significant components of the Company’s net deferred tax assets (liabilities) as of December 31, 2021 and 2020 were as follows (in thousands): December 31, 2021 2020 Deferred tax assets: Accrued expenses and other $ 510 $ 592 Intangibles 407 369 Net operating losses 14,683 6,046 Research and development credits 1,410 315 Stock based compensation 222 179 Lease Liability 760 485 Unrealized gain/loss 13 — Total deferred tax assets 18,005 7,986 Valuation allowance (17,682 ) (7,587 ) Total net deferred tax assets 323 399 Deferred tax liabilities: Right-of-use asset (302 ) (399 ) Fixed assets (21 ) — Total deferred tax liabilities (323 ) (399 ) Net deferred tax assets $ — $ — A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. The Company believes that, based on a number of factors such as the history of operating losses, it is more likely than not that the deferred tax assets will not be fully realized, such that a full valuation allowance has been recorded. The valuation allowance increased by $10.1 million and $6.2 million for the years ended December 31, 2021 and 2020, respectively. The following table sets forth the Company’s federal and state net operating loss carryforwards as of December 31, 2021 (amounts in thousands): Amount Expiration Years Net operating losses, Federal $ 53,071 Do not expire Net operating losses, states primarily California $ 45,442 2038 – 2041 As of December 31, 2021, the Company had research and development credit carryforwards of approximately $1.3 million and $1.0 million available to reduce future taxable income, if any, for both federal and California state income tax purposes, respectively. The federal research and development credit carryforwards begin expiring in 2040, and California credits carryforward indefinitely. Utilization of the net operating loss carryforwards and research credit carryforwards may be subject to an annual limitation due to the ownership percentage change limitations provided by the Internal Revenue Code, as amended (“IRC”), and similar state provisions. Annual limitations may result in the expiration of the net operating losses and tax credit carryforwards before they are utilized. As of December 31, 2021, the Company has completed an IRC Section 382 analysis from inception through the year ended December 31, 2021. Old Jasper experienced an ownership change on November 21, 2019 related to Series A redeemable convertible preferred stock financing. Any net operating loss generated in excess of the $2.9 million will be permanently limited for California tax purposes. The Company reduced its California net operating loss deferred tax assets balance by the permanently limited amount of $0.6 million. Net federal operating losses are not limited as they can be carried forward indefinitely. We experienced an additional ownership change on September 24, 2021. However, we do not expect there are additional tax attributes that will expire unused before the expiration periods. Uncertain Tax Positions A reconciliation of the beginning and ending balances of the unrecognized tax benefits during the periods ended December 31, 2021 and 2020 is as follows (in thousands): Year Ended December 31, 2021 2020 Balance at beginning of year $ 252 $ 17 Additions based on tax positions related to current year 576 235 Balance at end of year $ 828 $ 252 The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. Related to the unrecognized tax benefits noted above, the Company did not accrue any penalties or interest during tax years 2021 and 2020. The Company does not expect its unrecognized tax benefit to change materially over the next twelve months. The Company is subject to examination by the United States federal and state tax authorities for the tax years 2018 and later State income tax returns are generally subject to examination for a period of four years after filing of the respective return. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted and signed into law, and U.S. GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the Tax Cuts and Jobs Act of 2017. The tax relief measures for businesses include a five -year from net operating losses generated in a tax year beginning after December 31, 2017 through December 31, 2020, changes the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property. The CARES Act also provides other non -tax On December 21, 2020, the President of the United States signed into law the “Consolidated Appropriations Act, 2021”, which includes further COVID -19

401(K) Savings Plan

401(K) Savings Plan	12 Months Ended
	Dec. 31, 2021
Savings Plan [Abstract]
401(K) SAVINGS PLAN	NOTE 15. 401(K) SAVINGS PLAN The Company has a retirement and savings plan under Section 401(k) of the IRC (the “401(k) Plan”), covering all U.S. employees. The 401(k) Plan allows employees to make pre -tax

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 16. RELATED PARTIES Old Jasper entered into consulting agreements with two founders, who also received founders’ common stock shares for services and assigned patents. The founders transferred to Old Jasper $74,000 in intellectual property rights and $6,000 in cash as a consideration for common stock. The Company recorded $0.5 million and $0.3 million for the founders’ advisory and consulting services performed for the years ended December 31, 2021 and 2020, respectively. These expenses were recorded as research and development expenses in the consolidated statements of operations and comprehensive loss. Also, the Company’s Licensed Technology from Stanford (see Note 7) was created in the Stanford laboratory of one of the founders. In December 2020, the Company entered into a material transfer agreement with Zai Lab Limited where both companies will collaborate on a research project and share total expenses of up to $0.3 million equally. The Company recorded $36,000 as a reduction to research and development expenses for expenses reimbursed by Zai Lab Limited for the year ended December 31, 2021. No expenses were incurred or reimbursed under this agreement for the year ended December 31, 2020. The Company’s chairman is a board member of Zai Lab Limited.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 17. SUBSEQUENT EVENT Amendment to operating lease In January 2022, the Company amended its operating lease in Redwood City, California to add an additional 5,611 rentable square feet. The total additional lease payments for the extra space from the commencement date are estimated at $1.8 million. The Company’s operating lease will expire in August 2026.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and regulations of the U.S. Securities and Exchange Commission for financial reporting. The accompanying financial statements are consolidated for the year ended December 31, 2021 and include the accounts of Jasper Therapeutics, Inc. (i.e., formerly known as AMHC) and its wholly -owned All historical share data and per -share -2 -2
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to the valuation of common and redeemable convertible preferred stock before the Reverse Recapitalization, the determination of the incremental borrowing rate used for operating lease liabilities, valuation of derivative liability, valuation of earnout liability and the measurement of stock -based
Cash, Cash Equivalents, and Restricted Cash	Cash, Cash Equivalents, and Restricted Cash The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total amount shown in the consolidated statements of cash flows (in thousands): December 31, 2021 2020 Cash and cash equivalents $ 84,701 $ 19,838 Restricted cash 345 345 Total cash, cash equivalents and restricted cash $ 85,046 $ 20,183 Cash and cash equivalents consist of checking account and investments in money market funds with an original maturity of three months or less at the time of purchase. The recorded carrying amount of cash and cash equivalents approximates their fair value. Restricted cash relates to the letter of credit secured in conjunction with the operating lease (Note 9).
Concentrations of Credit Risk and Other Risks and Uncertainties	Concentrations of Credit Risk and Other Risks and Uncertainties The Company’s cash and cash equivalents are maintained with financial institutions in the United States of America. Management believes that these financial institutions are financially sound. The Company has not experienced any losses on its cash and cash equivalents. The Company is subject to risks common to companies in the development stage, including, but not limited to, development and regulatory approval of new product candidates, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product plans. To achieve profitable operations, the Company must successfully develop and obtain requisite regulatory approvals for, manufacture, and market its product candidates. There can be no assurance that any such product candidate can be developed and approved or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product will be successfully marketed. These factors could have a material adverse effect on the Company’s future financial results. Products developed by the Company require approval from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s future products will receive the necessary clearances. If the Company were denied such clearances or such clearances were delayed, it could have a materially adverse impact on the Company.
Deferred Transaction Costs	Deferred Transaction Costs The Company capitalized qualified legal, accounting, and other direct costs related to the Business Combination, which were deferred until completion of the Business Combination. Upon the completion of the Business Combination, all deferred costs were recorded as a reduction to additional paid -in
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight -line
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews its long -lived -lived -lived -lived
Leases	Leases The Company determines whether an arrangement is or contains a lease at the inception of the arrangement and whether such a lease is classified as a financing lease or operating lease at the commencement date of the lease. Leases with a term greater than one year are recognized on the balance sheet as operating right -of-use -current -of-use -term -of-use -of-use -of-use The Company considers the lease term to be the noncancelable period that it has the right to use the underlying asset, together with any periods where it is reasonably certain it will exercise an option to extend (or not terminate) the lease. Periods covered by an option to extend (or not terminate) the lease in which the exercise of the option is controlled by the lessor are included in the lease term. Rent expense for operating leases is recognized on a straight -line -lease -lease The Company has no finance leases as of December 31, 2021 and 2020.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities, derivative tranche liability, common stock warrant liability, contingent earnout liability and other non -current -based -term
Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock The Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs and bifurcated derivative tranche liability, which was bifurcated as it was concluded to be a freestanding financial instrument liability. The redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company’s control such as a merger, acquisition or sale of all or substantially all of the Company’s assets (each, a deemed liquidation event), the redeemable convertible preferred stock became redeemable at the option of the holders of at least 55% of the then outstanding shares. The Company did not adjust the carrying values of the redeemable convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock was not probable of occurring.
Common Stock Warrant Liability	Common Stock Warrant Liability The Company has outstanding warrants to purchase 4,999,883 -voting -voting -current
Contingent Earnout Liability	Contingent Earnout Liability At the closing of the Business Combination, the Company recognized the earnout liability related to the Sponsor Support Agreement, dated May 5, 2021 and amended on September 24, 2021, by and among the Company, Amplitude Healthcare Holdings LLC (the “Sponsor”) and Old Jasper (as amended, the “Sponsor Support Agreement”), pursuant to which 1,050,000 -40
Derivative Tranche Liability	Derivative Tranche Liability The Company determined that its obligation to issue additional shares of redeemable convertible preferred stock upon the occurrence of certain events, including a number of patients enrolled in the clinical trials, or the consent of the Company’s Board of Directors (the “Board”), represented a freestanding financial instrument. The instrument was classified as a liability on the consolidated balance sheets and was subject to re -measurement
Accrued Research and Development Expenses	Accrued Research and Development Expenses The Company has entered into various agreements with outsourced vendors, CMOs and CROs. The Company makes estimates of accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.
Research and Development	Research and Development The Company expenses research and development (“R&D”) expenses as incurred. R&D expenses consist primarily of personnel -related -related -based -related
General and Administrative	General and Administrative General and administrative expenses include compensation, employee benefits and stock -based
Stock-Based Compensation	Stock-Based Compensation The Company measures its stock -based -employees -Scholes -pricing -free -based -line -based
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction -by-jurisdiction Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. To date, there have been no interest or penalties recorded in relation to unrecognized tax benefits.
Foreign Currency Transactions	Foreign Currency Transactions Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re -measured -measured
Comprehensive loss	Comprehensive loss Comprehensive loss represents all changes in stockholders’ equity (deficit) except those resulting from distributions to stockholders. There have been no items qualifying as other comprehensive income (loss) during the years ended December 31, 2021 and 2020, and therefore, the Company’s comprehensive loss was the same as its reported net loss.
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted -average -average Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two -class obligation to share in the Company’s losses. As such, the net loss is attributed entirely to common stockholders. For the years ended December 31, 2021 and 2020, the diluted net loss per share of common stock was the same as basic net loss per share of common stock, as the impact of potentially dilutive securities was antidilutive to the net loss per share. The Earnout Shares and common stock subject to restricted stock awards are contingently issuable shares and are not included in the diluted net loss per share calculation until contingencies are resolved.
Segment Reporting	Segment Reporting The Company has determined it operates as a single operating and reportable segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources. All long -lived
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2019 -12

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of reconciliation of cash equivalents and restricted cash	December 31, 2021 2020 Cash and cash equivalents $ 84,701 $ 19,838 Restricted cash 345 345 Total cash, cash equivalents and restricted cash $ 85,046 $ 20,183

Reverse Recapitalization (Table

Reverse Recapitalization (Tables)	12 Months Ended
	Dec. 31, 2021
Reverse Recapitalization [Abstract]
Schedule of shares of common stock issued and outstanding	Number of Common stock of AMHC outstanding prior to the Business Combination 12,500,000 Less: shares forfeited by the Sponsor (200,000 ) Less: redemption of AMHC shares (9,262,099 ) Common stock of AMHC 3,037,901 Shares issued in the PIPE Financing 10,000,000 Business Combination and PIPE Financing shares 13,037,901 Old Jasper shares 24,778,409 Total shares of common stock immediately after the Business Combination 37,816,310

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of financial assets and liabilities	December 31, 2021 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 83,701 $ — $ — $ 83,701 Total fair value of assets $ 83,701 $ — $ — $ 83,701 Financial liabilities Common stock warrant liability $ 7,350 $ — $ — $ 7,350 Earnout liability — — 5,743 5,743 Total fair value of financial liabilities $ 7,350 $ — $ 5,743 $ 13,093 December 31, 2020 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 18,778 $ — $ — $ 18,778 Total fair value of assets $ 18,778 $ — $ — $ 18,778 Financial liabilities Derivative liability $ — $ — $ 8,158 $ 8,158 Total fair value of financial liabilities $ — $ — $ 8,158 $ 8,158
Schedule of changes in the fair value	Derivative Earnout Fair Value as of January 1, 2020 $ 4,053 $ — Initial fair value of derivative instrument — — Change in the fair value included in other expense 10,875 — Settlement of obligation (6,770 ) — Fair Value as of December 31, 2020 $ 8,158 $ — Fair Value as of January 1, 2021 $ 8,158 $ — Initial fair value of earnout liability — 15,020 Change in the fair value included in other expense (income) 3,501 (9,277 ) Settlement of obligation (11,659 ) — Fair Value as of December 31, 2021 $ — $ 5,743
Schedule of fair value measurements	Fair value Valuation Significant unobservalble input Earnout liability $ 5,743 Monte Carlo Simulation Common stock price $ 7.85 Expected term (in years) 2.73 Expected volatility 74.00 % Risk -free 0.90 % Fair value Valuation Significant unobservalble input Derivative tranche liability $ 8,158 Black -Scholes Expected term (in years) 0.16 Expected volatility 47.02 % Risk -free 0.08 % Expected dividend yield 0.00 %

Consolidated Balance Sheet Co_2

Consolidated Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2021
Condensed Financial Information Disclosure [Abstract]
Schedule of prepaid expenses and other current assets	December 31, 2021 2020 Prepaid insurance $ 2,074 $ — Payroll tax credit receivable 548 — Research and development prepaid expenses 139 177 Other receivables 150 — Other prepaid expenses 171 43 Rent deposit 27 27 Other current assets 21 — Total $ 3,130 $ 247
Schedule of property and equipment	December 31, 2021 2020 Leasehold improvements $ 2,056 $ 256 Lab equipment 1,569 437 Office furniture & fixtures 208 — Computer equipment 140 — Capitalized software 90 — 4,063 693 Less: accumulated depreciation and amortization (377 ) — Property and equipment, net $ 3,686 $ 693
Schedule of accrued expenses and other current liabilities	December 31, 2021 2020 Research and development accrued expenses $ 1,660 $ 1,263 Accrued employee and related compensation expenses 1,151 783 License option liability, current 200 400 Other 585 149 Total $ 3,596 $ 2,595
Schedule of other non-current liabilities	December 31, 2021 2020 CIRM grant liability $ 600 $ 600 Accrued tax liability 24 — Restricted stock liability 19 53 License option liability, non-current — 200 Total $ 643 $ 853

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of business combination the estimated fair value	February 26, Series A-1 redeemable convertible preferred stock value $ 1.57 Purchase price $ 0.75 Expected term (in years) — Expected volatility 0.00 % Risk-free interest rate 0.00 % September 24, Common stock value $ 15.12 Expected term (in years) 3.00 Expected volatility 75.00 % Risk-free interest rate 0.55 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of components of lease costs	Year ended December 31, 2021 2020 Lease cost Operating lease cost* $ 479 $ 45 Short-term lease cost 326 301 Total lease cost $ 805 $ 346
Schedule of operating leases	Year ended December 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities $ 301 $ — Weighted average remaining lease term (years) 4.6 5.4 Weighted average discount rate 8.00 % 8.00 %
Schedule of operating lease liabilities showing aggregate lease payments	Amount Year ending December 31, 2022 $ 713 2023 735 2024 757 2025 779 2026 461 Total undiscounted lease payments 3,445 Less imputed interest (560 ) Total discounted lease payments 2,885 Less current portion of lease liability (505 ) Noncurrent portion of lease liability $ 2,380

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2021
Redeemable Convertible Preferred Stock Details [Abstract]
Schedule of redeemable convertible preferred stock	December 31, 2020 Shares Authorized Shares Aggregate Net Series A-1 redeemable convertible preferred stock 19,522,671 15,480,095 $ 41,165 $ 42,978 Series A-2 redeemable convertible preferred stock 100 100 — 862 Total redeemable convertible preferred stock 19,522,771 15,480,195 $ 41,165 $ 43,840

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2021
Common Stock [Abstract]
Schedule of reserved common stock for future issuance	December 31, 2021 2020 Redeemable convertible preferred stock — 15,480,195 Outstanding and issued common stock options 2,660,383 2,983,574 Common stock warrants 4,999,883 — Shares available for grant under 2019 Equity Incentive Plan — 430,893 Shares available for grant under 2021 Equity Incentive Plan 4,422,480 — Shares available for grant under 2021 Employee Stock Purchase Plan 550,000 — Total shares of common stock reserved 12,632,746 18,894,662

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock option activity	Option Outstanding Weighted Aggregate Shares Number of Weighted Balance, January 1, 2021 430,893 2,983,574 $ 0.71 9.52 $ 5,599,957 Shares available for grant cancelled (407,864 ) Shares authorized 4,400,000 Options granted (145,753 ) 145,753 $ 2.59 Options exercised — (323,740 ) $ 0.72 Options cancelled/forfeited 145,204 (145,204 ) $ 0.72 Balance, December 31, 2021 4,422,480 2,660,383 $ 0.81 8.54 $ 18,731,908 Vested and expected to vest, December 31, 2021 2,660,383 $ 0.81 8.54 $ 18,731,908 Exercisable 1,568,645 $ 0.71 8.74 $ 13,642,291
Schedule of stock-based compensation expense	Year Ended December 31, 2021 2020 Research and development $ 612 $ 488 General and administrative 436 722 Total $ 1,048 $ 1,210
Schedule of fair value of employee stock options was estimated using a Black-Scholes option-pricing model	Year Ended December 31, 2021 2020 Expected term (in years) 5.29 – 6.08 5.00 – 6.06 Expected volatility 75.27% – 75.79% 74.27% – 75.61% Risk-free interest rate 0.65% – 0.80% 0.27% – 0.45% Expected dividend yield — —

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per share attributable to common stockholders	Year Ended December 31, 2021 2020 Numerator: Net loss attributable to common stockholders $ (30,637 ) $ (31,669 ) Denominator: Weighted average common shares outstanding 12,363,677 2,697,181 Less: Weighted-average unvested restricted shares (685,129 ) (967,363 ) Less: Weighted-average shares subject to earnout (284,795 ) — Weighted average shares used to compute basic and diluted net loss per share 11,393,753 1,729,818 Net loss per share attributable to common stockholders – basic and diluted $ (2.69 ) $ (18.31 )
Schedule of diluted net loss per share attributable to common stockholders	December 31, 2021 2020 Common stock warrants 4,999,883 — Outstanding and issued common stock options 2,660,383 2,983,574 Unvested restricted common stock 541,225 823,603 Convertible preferred stock — 15,480,195 Total 8,201,491 19,287,372

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of provision for income taxes rate	Year Ended December 31, 2021 2020 Federal tax benefit at statutory rate $ (6,433 ) $ (6,651 ) State taxes (1,729 ) (1,757 ) Change in fair value of derivative 735 2,284 Change in fair value of warrant liability (105 ) — Change in fair value of earnout liability (1,948 ) — Non-deductible expenses 633 231 Research and development credits (1,095 ) (298 ) Change in valuation allowance 10,095 6,191 Other (153 ) — Provision for income taxes $ — $ —
Schedule of company’s net deferred tax assets (liabilities)	December 31, 2021 2020 Deferred tax assets: Accrued expenses and other $ 510 $ 592 Intangibles 407 369 Net operating losses 14,683 6,046 Research and development credits 1,410 315 Stock based compensation 222 179 Lease Liability 760 485 Unrealized gain/loss 13 — Total deferred tax assets 18,005 7,986 Valuation allowance (17,682 ) (7,587 ) Total net deferred tax assets 323 399 Deferred tax liabilities: Right-of-use asset (302 ) (399 ) Fixed assets (21 ) — Total deferred tax liabilities (323 ) (399 ) Net deferred tax assets $ — $ —
Schedule of company’s federal and state net operating loss carryforwards	Amount Expiration Years Net operating losses, Federal $ 53,071 Do not expire Net operating losses, states primarily California $ 45,442 2038 – 2041
Schedule of reconciliation of unrecognized tax benefits	Year Ended December 31, 2021 2020 Balance at beginning of year $ 252 $ 17 Additions based on tax positions related to current year 576 235 Balance at end of year $ 828 $ 252

Organization and Description _2

Organization and Description of Business (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization and Description of Business (Details) [Line Items]
Incurred net losses	$ 30.6	$ 31.7
Operating cash flows	33.7	$ 18.3
Accumulated deficit	67.5
Cash and cash equivalents	$ 84.7
Class A Common Stock [Member]
Organization and Description of Business (Details) [Line Items]
Purchase of aggregate shares (in Shares)	10,000,000
Share price per unit (in Dollars per share)	$ 10
Aggregate gross proceeds	$ 100

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Summary of Significant Accounting Policies (Details) [Line Items]
Lease term	1 year
Preferred stock percentage	55.00%
Common stock, shares issued	1,050,000
Minimum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Property plant and equipment useful life	3 years
Maximum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Property plant and equipment useful life	5 years
Common Stock [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Converted shares	2,200,000
Common Stock Warrants [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Warrants outstanding	4,999,883
Exercise price | $ / shares	$ 11.5

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of cash equivalents and restricted cash - Cash Cash Equivalents and Restricted Cash [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Restricted Cash and Cash Equivalents Items [Line Items]
Cash and cash equivalents	$ 84,701	$ 19,838
Restricted cash	345	345
Total cash, cash equivalents and restricted cash	$ 85,046	$ 20,183

Reverse Recapitalization (Detai

Reverse Recapitalization (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2021
Reverse Recapitalization (Details) [Line Items]
Cash at price (in Dollars per share)	$ 0.04
Investors shares (in Shares)		10,000,000
Gross proceeds		$ 100
Business combination description		each share of Old Jasper common stock and Old Jasper redeemable convertible preferred stock outstanding immediately prior to the closing was automatically cancelled, extinguished and converted into the number of shares of the Company’s common stock or, in certain circumstances, the Company’s non-voting common stock, based on Old Jasper’s equity value of $275.0 million divided by $10.00. The exchange ratio agreed between the parties was one-for-0.282378 share of the Company’s common stock for all Old Jasper stockholders, except for Amgen Inc. (“Amgen”).
Common stock represented percentage		8.00%
Common stock voting outstanding (in Shares)		36,520,288
Common stock subject to restricted stock awards (in Shares)		611,818
Common stock non-voting outstanding (in Shares)		1,296,022
Common stock subject to outstanding options (in Shares)		2,721,557
Net proceeds		$ 95.3
Cash held in trust account		5.5
Cash received		100
Payments of operating expense		1.2
Transaction costs		5.3
Net assets		0.6
Warrant liability		7.9
Fair value earnout liability		15
AMHC [Member]
Reverse Recapitalization (Details) [Line Items]
Transaction costs and placement agents fees		$ 9
AMHC [Member]
Reverse Recapitalization (Details) [Line Items]
Common stock price per share (in Dollars per share)		$ 10
Sponsor [Member]
Reverse Recapitalization (Details) [Line Items]
Business combination description		(i) the Sponsor forfeited 200,000 shares of AMHC’s Class B common stock, (ii) each share of AMHC’s Class B common stock outstanding was converted into one share of AMHC’s Class A common stock, and (iii) following such conversion, an aggregate of 13,037,901 shares of AMHC’s Class A common stock (inclusive of 10,000,000 shares of AMHC’s Class A common stock that were issued to the PIPE Investors) were converted into an equivalent number of shares of the Company’s voting common stock. In accordance with the Sponsor Support Agreement, 1,050,000 shares received by the Sponsor were placed in escrow and will be released upon meeting triggering events as defined in the agreement and as described in Note 8 below.
Class A Common stock [Member]
Reverse Recapitalization (Details) [Line Items]
Common stock exercised (in Shares)		9,262,099
Aggregate payments		$ 92.7
Class A Common stock [Member] | AMHC [Member]
Reverse Recapitalization (Details) [Line Items]
Cash at price (in Dollars per share)		$ 10.01
Series A-2 Redeemable Convertible Preferred Stock [Member]
Reverse Recapitalization (Details) [Line Items]
Convertible preferred stock shares (in Shares)		2,200,000

Reverse Recapitalization (Det_2

Reverse Recapitalization (Details) - Schedule of shares of common stock issued and outstanding	12 Months Ended
	Dec. 31, 2021shares
Schedule of shares of common stock issued and outstanding [Abstract]
Common stock of AMHC outstanding prior to the Business Combination	12,500,000
Less: shares forfeited by the Sponsor	(200,000)
Less: redemption of AMHC shares	(9,262,099)
Common stock of AMHC	3,037,901
Shares issued in the PIPE Financing	10,000,000
Business Combination and PIPE Financing shares	13,037,901
Old Jasper shares	24,778,409
Total shares of common stock immediately after the Business Combination	37,816,310

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of financial assets and liabilities - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Financial assets
Money market funds	$ 83,701	$ 18,778
Total fair value of assets	83,701	18,778
Financial liabilities
Derivative liability		8,158
Financial liabilities
Common stock warrant liability	7,350
Earnout liability	5,743
Total fair value of financial liabilities	13,093	8,158
Level 1 [Member]
Financial assets
Money market funds	83,701	18,778
Total fair value of assets	83,701	18,778
Financial liabilities
Derivative liability
Financial liabilities
Common stock warrant liability	7,350
Earnout liability
Total fair value of financial liabilities	7,350
Level 2 [Member]
Financial assets
Money market funds
Total fair value of assets
Financial liabilities
Derivative liability
Financial liabilities
Common stock warrant liability
Earnout liability
Total fair value of financial liabilities
Level 3 [Member]
Financial assets
Money market funds
Total fair value of assets
Financial liabilities
Derivative liability		8,158
Financial liabilities
Common stock warrant liability
Earnout liability	5,743
Total fair value of financial liabilities	$ 5,743	$ 8,158

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of changes in the fair value - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Derivative tranche liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, beginning	$ 8,158	$ 4,053
Initial fair value of derivative instrument
Initial fair value of earnout liability
Change in fair value included in other expense (income)	3,501	10,875
Settlement of obligation	(11,659)	(6,770)
Fair value, ending		8,158
Earnout liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, beginning
Initial fair value of derivative instrument
Initial fair value of earnout liability	15,020
Change in fair value included in other expense (income)	(9,277)
Settlement of obligation
Fair value, ending	$ 5,743

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of fair value measurements - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Earnout liability [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in Dollars)	$ 5,743
Valuation methodology	Monte Carlo Simulation
Common stock price (in Dollars per share)	$ 7.85
Expected term (in years)	2 years 8 months 23 days
Expected volatility	74.00%
Risk-free interest rate	0.90%
Derivative tranche liability [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in Dollars)		$ 8,158
Valuation methodology		Black-Scholes
Common stock price (in Dollars per share)		$ 0.16
Expected term (in years)		47 years 7 days
Expected volatility		0.08%
Risk-free interest rate		0.00%

Consolidated Balance Sheet Co_3

Consolidated Balance Sheet Components (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Condensed Financial Information Disclosure [Abstract]
Depreciation and amortization expense	$ 0.4

Consolidated Balance Sheet Co_4

Consolidated Balance Sheet Components (Details) - Schedule of prepaid expenses and other current assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of prepaid expenses and other current assets [Abstract]
Prepaid insurance	$ 2,074
Payroll tax credit receivable	548
Research and development prepaid expenses	139	177
Other receivables	150
Other prepaid expenses	171	43
Rent deposit	27	27
Other current assets	21
Total	$ 3,130	$ 247

Consolidated Balance Sheet Co_5

Consolidated Balance Sheet Components (Details) - Schedule of property and equipment - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of property and equipment [Abstract]
Leasehold improvements	$ 2,056	$ 256
Lab equipment	1,569	437
Office furniture & fixtures	208
Computer equipment	140
Capitalized software	90
Total property and equipment	4,063	693
Less: accumulated depreciation and amortization	(377)
Property and equipment, net	$ 3,686	$ 693

Consolidated Balance Sheet Co_6

Consolidated Balance Sheet Components (Details) - Schedule of accrued expenses and other current liabilities - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of accrued expenses and other current liabilities [Abstract]
Research and development accrued expenses	$ 1,660	$ 1,263
Accrued employee and related compensation expenses	1,151	783
License option liability, current	200	400
Other	585	149
Total	$ 3,596	$ 2,595

Consolidated Balance Sheet Co_7

Consolidated Balance Sheet Components (Details) - Schedule of other non-current liabilities - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of other non-current liabilities [Abstract]
CIRM grant liability	$ 600	$ 600
Accrued tax liability	24
Restricted stock liability	19	53
License option liability, non-current		200
Total	$ 643	$ 853

Cirm Grant (Details)

Cirm Grant (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Mar. 31, 2021	Nov. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Cirm Grant Disclosure [Abstract]
Research project related cost		$ 2.3
Percentage of licensing fees			0.10%
CIRM fund technology			$ 1
Percentage of converted loan			60.00%
Received from interest rate			25.00%
Other receivables milestone				$ 0.6
Other long-term liabilities			$ 0.6	$ 0.6
Received aggregate from CIRM	$ 0.6
Future distribution to company under grant value			$ 1.7

Significant Agreements (Details

Significant Agreements (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Nov. 21, 2019	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2020	Jun. 30, 2020
Significant Agreements (Details) [Line Items]
Amount paid for option exercise fee		$ 0.2		$ 0.2	$ 0.2
Current liabilities			$ 0.4
Noncurrent liabilities			$ 0.2
Accrued expenses and other current liabilities		$ 0.4
Related party, interest rate		5.00%
Annual license maintenance fees description		The Company will pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and second year, $35,000 for each third and fourth year, and $50,000 at each anniversary thereafter ending upon the first commercial sale.
Sales milestone payments		$ 9
Series A-2 Redeemable Convertible Preferred Stock [Member]
Significant Agreements (Details) [Line Items]
Research and development cost	$ 0.9
Convertible preferred stock (in Shares)	100
ISRA [Member]
Significant Agreements (Details) [Line Items]
Exercise fee		1
Research and development cost		$ 1

Derivative Financial Instrume_3

Derivative Financial Instruments (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Sep. 24, 2021	Feb. 28, 2021	Nov. 30, 2020	Nov. 30, 2019
Derivative Financial Instruments (Details) [Line Items]
Fair value							$ 4.3
Shares, issued (in Shares)				2,200,000
Derivative tranche liability		$ 3.5	$ 10.9
Market fair value				$ 7.9
Recognized gain		0.5
Change in fair value		$ 7.4
Description of contingent earnout liability		Upon the closing of the Business Combination and pursuant to the Sponsor Support Agreement, the Sponsor agreed to place the Earnout Shares into escrow, which will be released as follows: (a) 250,000 Earnout Shares will be released if, during the period from and after September 24, 2021 until the September 24, 2024 (the “Earnout Period”), over any twenty trading days within any thirty-day consecutive trading day period, the volume-weighted average price of the Company’s common stock (the “Applicable VWAP”) is greater than or equal to $11.50, (b) 500,000 Earnout Shares will be released if, during the Earnout Period, the Applicable VWAP is greater than or equal to $15.00, and (c) 300,000 Earnout Shares will be released if, during the Earnout Period, the Applicable VWAP is greater than or equal to $18.00 (the “triggering events”).
Estimated fair value of earnout liability		$ 15
Monte Carlo Valuation Model [Member]
Derivative Financial Instruments (Details) [Line Items]
Estimated fair value of earnout liability		$ 5.7
Contingent Earnout Liability [Member]
Derivative Financial Instruments (Details) [Line Items]
Recognized gain	$ 9.3
Redeemable Convertible Preferred Stock [Member]
Derivative Financial Instruments (Details) [Line Items]
Fair value					$ 11.7	$ 6.8
Series A-1 Redeemable Convertible Preferred Stock [Member]
Derivative Financial Instruments (Details) [Line Items]
Shares, issued (in Shares)					4,042,565	4,042,568

Derivative Financial Instrume_4

Derivative Financial Instruments (Details) - Schedule of business combination the estimated fair value - $ / shares	7 Months Ended
	Sep. 24, 2021	Feb. 26, 2021
Schedule of business combination the estimated fair value [Abstract]
Series A-1 redeemable convertible preferred stock value (in Dollars per share)		$ 1.57
Purchase price		0.75%
Expected term (in years)	3 years
Expected volatility	75.00%	0.00%
Risk-free interest rate	0.55%	0.00%
Common stock value (in Dollars per share)	$ 15.12

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	1 Months Ended		12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Lessor amount			$ 300,000
Improvement allowance,description			To complete certain leasehold improvements, the lessor agreed to provide the Company a tenant improvement allowance of $1.2 million as well as an option to take an additional allowance of $0.4 million to be repaid over the lease term at an interest rate of 9% per annum, which the Company exercised.
Improvement allowance			$ 1,200,000
Additional Liability, Long-Duration Insurance, Reinsurance Recoverable, after Allowance			$ 400,000
Interest rate per annum,percentage			9.00%
Leasehold improvements		$ 300,000	$ 1,600,000	$ 300,000
Net construction costs, percentage			5.00%
Variable lease cost			$ 90,000	13,000
Operating expenses or taxes			$ 50,000
Pay stanford net				$ 900,000
Pay stanford net term				3 years
First milestone agreement paid		$ 300,000
License agreements, description	on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and second year, $35,000 for each third and fourth year, and $50,000 at each anniversary thereafter ending upon the first commercial sale. The Company is also obligated to pay late-stage clinical development milestones and first commercial sales milestone payments of up to $9.0 million in total.

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of components of lease costs - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Lease cost
Operating lease cost	[1]	$ 479	$ 45
Short-term lease cost		326	301
Total lease cost		$ 805	$ 346
[1]	Includes $90,000 and $13,000 of variable lease cost related to the construction management and supervision fee during the years ended December 31, 2021 and 2020, respectively, and $50,000 variable costs related to operating expenses or taxes during the year ended December 31, 2021. No variable costs related to operating expenses or taxes have been incurred as of December 31, 2020.

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of operating leases - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of operating leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities (in thousands)	$ 301
Weighted average remaining lease term (years)	4 years 7 months 6 days	5 years 4 months 24 days
Weighted average discount rate	8.00%	8.00%

Commitments and Contingencies_5

Commitments and Contingencies (Details) - Schedule of operating lease liabilities showing aggregate lease payments $ in Thousands	Dec. 31, 2021USD ($)
Schedule of operating lease liabilities showing aggregate lease payments [Abstract]
2022	$ 713
2023	735
2024	757
2025	779
2026	461
Total undiscounted lease payments	3,445
Less imputed interest	(560)
Total discounted lease payments	2,885
Less current portion of lease liability	(505)
Noncurrent portion of lease liability	$ 2,380

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred Stock (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 24, 2021	Dec. 31, 2021
Redeemable Convertible Preferred Stock (Details) [Line Items]
Convertible preferred stock (in Shares)	21,722,661
Common stock shares issued (in Shares)	2,200,000
Common stock shares investor (in Shares)	1,296,022
Cash dividends rate percentage		8.00%
Original issue price (in Dollars)		$ 2.6592
Conversion rights, description		Each share of Series A-1 redeemable convertible preferred stock was convertible to Class A common stock, at the option of the holder, at the then applicable conversion price. Any holder that beneficially owned, directly or indirectly, more than 9.9% of any class of equity securities had the right to receive any shares of capital stock that would have been issued upon conversion of the shares in excess of 9.9% in the form of Class B common stock. The initial conversion price per share for Series A-1 redeemable convertible preferred stock was $2.6592. Shares of Series A-2 redeemable convertible preferred stock were not convertible at the option of the holder.Each share of Series A-1 redeemable convertible preferred stock would have been automatically converted into common stock, at the then effective conversion price (i) immediately prior to closing of the initial public offering at a common stock per share price of at least five times the original issue price of the Series A-1 redeemable convertible preferred stock resulting in at least $70.0 million of gross proceeds, or (ii) at the date and time, or upon occurrence of an event, specified by vote or written consent of the holders of at least 55% of the outstanding shares of Series A-1 redeemable convertible preferred stock.Upon Old Jasper’s initial public offering, each share of Series A-2 redeemable convertible preferred would have been automatically converted into a number of shares of Class A common stock equal to 8% of the fully diluted equity immediately prior to such initial public offering. The percentage of Class A common stock subject to Series A-2 redeemable convertible preferred stock conversion would have been reduced to 4% if the Company terminated the Amgen License Agreement, or Amgen was pursuing a clinical development of an anti c-kit antibody in any clinical indication for which the Company had filed or held an IND for an anti c-kit antibody.
Convertible preferred stock or common stock per share (in Dollars per share)		$ 0.25
Adjusted for stock splits, dividends (in Dollars)		$ 2.6592
Amgen License Agreement [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Preferred stock rate percentage		4.00%
Redeemable Convertible Preferred Stock [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Cash dividends rate percentage		8.00%
Conversion rights, description		Provided, however, that if the aggregate amount which the holders of Series A-1 redeemable convertible preferred stock were entitled to receive under the above provisions exceeded 1.5 times the applicable original issue price of $2.6592, as adjusted for stock splits, dividends, reclassifications or the like, upon such liquidation, dissolution or winding up the holders of Series A-1 redeemable convertible preferred stock would have been entitled to receive the greater of (i) 1.5 times the applicable original issue price and (ii) the amount would have received if all shares of Series A-1 redeemable convertible preferred stock had been converted into common stock immediately prior to such liquidation, dissolution or winding up of the corporation.
Convertible preferred stock or common stock per share (in Dollars per share)		$ 0.75
Adjusted for stock splits, dividends (in Dollars)		$ 2.6592
Redeemable Convertible Preferred Stock [Member] | Amgen License Agreement [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Preferred stock rate percentage		4.00%

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred Stock (Details) - Schedule of redeemable convertible preferred stock	Dec. 31, 2020USD ($)shares
Series A-1 Redeemable Convertible Preferred Stock [Member]
Conversion of Stock [Line Items]
Shares Authorized | shares	19,522,671
Shares Issued and Outstanding | shares	15,480,095
Aggregate Liquidation Preference | $	$ 41,165,000
Net Carrying Value | $	$ 42,978,000
Series A-2 Redeemable Convertible Preferred Stock [Member]
Conversion of Stock [Line Items]
Shares Authorized | shares	100
Shares Issued and Outstanding | shares	100
Aggregate Liquidation Preference | $
Net Carrying Value | $	$ 862,000
Total Redeemable Convertible Preferred Stock [Member]
Conversion of Stock [Line Items]
Shares Authorized | shares	19,522,771
Shares Issued and Outstanding | shares	15,480,195
Aggregate Liquidation Preference | $	$ 41,165,000
Net Carrying Value | $	$ 43,840,000

Common Stock (Details)

Common Stock (Details) - USD ($)	Sep. 24, 2021	Mar. 31, 2018	Dec. 31, 2021
Common Stock (Details) [Line Items]
Common stock shares, issued		2,259,024
Shares of voting common stock	23,482,387		36,559,092
Shares of non-voting common stock	1,296,022		1,296,022
Authorized to issue of voting common stock			490,000,000
Shares of undesignated preferred stock			10,000,000
Voting common stock percentage			9.90%
Common stock per share (in Dollars per share)		$ 0.04
Cash received (in Dollars)		$ 6,000
Estimated fair value (in Dollars)		$ 100,000
Shares issued percentage		25.00%
Restricted stock liability (in Dollars)			$ 100,000
Unvested shares of common stock (in Dollars per share)			$ 541,225
Stock-based compensation expense (in Dollars)			$ 4,000
Unrecognized stock based compensation expense (in Dollars)			$ 8,000
Expected to be recognized term			1 year 10 months 24 days
Common Stock [Member]
Common Stock (Details) [Line Items]
Shares of non-voting common stock			2,000,000
Class A Common Stock [Member]
Common Stock (Details) [Line Items]
Common stock shares, issued	13,037,901

Common Stock (Details) - Schedu

Common Stock (Details) - Schedule of reserved common stock for future issuance - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of reserved common stock for future issuance [Abstract]
Redeemable convertible preferred stock		15,480,195
Outstanding and issued common stock options	2,660,383	2,983,574
Common stock warrants	4,999,883
Shares available for grant under 2019 Equity Incentive Plan		430,893
Shares available for grant under 2021 Equity Incentive Plan	4,422,480
Shares available for grant under 2021 Employee Stock Purchase Plan	550,000
Total shares of common stock reserved	12,632,746	18,894,662

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock-Based Compensation (Details) [Line Items]
Equity incentive plan description	(i) 2,750,000 shares, (ii) a number of shares equal to 4% of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares determined by the Board no later than the last day of the immediately preceding fiscal year. The number of shares of common stock available for issuance under the 2021 ESPP will increase annually in an amount equal to the least of (i) 550,000 shares of common stock, (ii) a number of shares of common stock equal to 1% of the total number of shares of all classes of common stock of the Company on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Board.
Fair market value of common stock percentage	85.00%
Common stock remain outstanding and unexercised (in Shares)	2,660,383
Total intrinsic value	$ 2,100,000	$ 100,000
Total fair value	$ 1,400,000	$ 800,000
Weighted-average grant date fair value per share (in Dollars per share)	$ 2.66	$ 0.32
Unvested stock based compensation	$ 1,500,000
Weighted average period	2 years 7 months 6 days
Expected dividend yield	$ 0
Under 2019 Plan and 2021 Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Voting rights	options are granted at an exercise price of not less than 100% of the fair market value of the common stock on the date of grant. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. Options become exercisable and expire as specified in the award agreement, provided that the term of options may not exceed 10 years from the date of grant (5 years for the individuals holding more than 10% of the voting rights of all classes of stock). Stock option agreements may provide for accelerated exercisability in the event of an optionee’s death, disability, retirement or other events. Vesting conditions determined by the administrator of the applicable plan may apply to stock options and may include continued service, performance and/or other conditions. Generally, stock options vest over a four-year period.
2021 Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Shares reserved and available for grants (in Shares)	4,422,480
2021 Employee Stock Purchase Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Shares reserved and available for grants (in Shares)	550,000

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of stock option activity	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Schedule of stock option activity [Abstract]
Shares Available for Grant, at beginning	430,893
Number of Shares, at beginning	2,983,574
Weighted Average Exercise Price, at beginning (in Dollars per share) | $ / shares	$ 0.71
Weighted - Average Remaining Contractual Life (Years), at beginning	9 years 6 months 7 days
Aggregate Intrinsic Value, at beginning (in Dollars) | $	$ 5,599,957
Shares Available for Grant, at ending	4,422,480
Number of Shares, at ending	2,660,383
Weighted Average Exercise Price, at ending (in Dollars per share) | $ / shares	$ 0.81
Weighted - Average Remaining Contractual Life (Years), at ending	8 years 6 months 14 days
Aggregate Intrinsic Value, at ending (in Dollars) | $	$ 18,731,908
Shares available for grant, Cancelled	(407,864)
Shares Available for Grant, Shares authorized	4,400,000
Shares Available for Grant, Options granted	(145,753)
Number of Shares, Options granted	145,753
Weighted Average Exercise Price, Options granted (in Dollars per share) | $ / shares	$ 2.59
Shares Available for Grant, Options exercised
Number of Shares, Options exercised	(323,740)
Weighted Average Exercise Price, Options exercised (in Dollars per share) | $ / shares	$ 0.72
Shares Available for Grant, Options cancelled/forfeited	145,204
Number of Shares, Options cancelled/forfeited	(145,204)
Weighted Average Exercise Price, Options cancelled/forfeited (in Dollars per share) | $ / shares	$ 0.72
Number of Shares, Vested and expected to vest	2,660,383
Weighted Average Exercise Price, Vested and expected to vest (in Dollars per share) | $ / shares	$ 0.81
Weighted - Average Remaining Contractual Life (Years), Vested and expected to vest	8 years 6 months 14 days
Aggregate Intrinsic Value, Vested and expected to vest (in Dollars) | $	$ 18,731,908
Number of Shares, Exercisable	1,568,645
Weighted Average Exercise Price, Exercisable (in Dollars per share) | $ / shares	$ 0.71
Weighted - Average Remaining Contractual Life (Years), Exercisable	8 years 8 months 26 days
Aggregate Intrinsic Value, Exercisable (in Dollars) | $	$ 13,642,291

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of stock-based compensation expense - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of stock-based compensation expense [Abstract]
Research and development	$ 612	$ 488
General and administrative	436	722
Total	$ 1,048	$ 1,210

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of fair value of employee stock options was estimated using a Black-Scholes option-pricing model	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock-Based Compensation (Details) - Schedule of fair value of employee stock options was estimated using a Black-Scholes option-pricing model [Line Items]
Expected dividend yield
Minimum [Member]
Stock-Based Compensation (Details) - Schedule of fair value of employee stock options was estimated using a Black-Scholes option-pricing model [Line Items]
Expected term (in years)	5 years 3 months 14 days	5 years
Expected volatility	75.27%	74.27%
Risk-free interest rate	0.65%	0.27%
Maximum [Member]
Stock-Based Compensation (Details) - Schedule of fair value of employee stock options was estimated using a Black-Scholes option-pricing model [Line Items]
Expected term (in years)	6 years 29 days	6 years 21 days
Expected volatility	75.79%	75.61%
Risk-free interest rate	0.80%	0.45%

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders (Details)	Dec. 31, 2021$ / shares
Earnings Per Share [Abstract]
Weighted-average number of shares of common stock outstanding	$ 0.282378

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of basic and diluted net loss per share attributable to common stockholders - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net loss attributable to common stockholders (in Dollars)	$ (30,637)	$ (31,669)
Denominator:
Weighted average common shares outstanding	12,363,677	2,697,181
Less: Weighted-average unvested restricted shares	(685,129)	(967,363)
Less: Weighted-average shares subject to earnout	(284,795)
Weighted average shares used to compute basic and diluted net loss per share	11,393,753	1,729,818
Net loss per share attributable to common stockholders – basic and diluted (in Dollars per share)	$ (2.69)	$ (18.31)

Net Loss Per Share Attributab_5

Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of diluted net loss per share attributable to common stockholders - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of diluted net loss per share attributable to common stockholders [Abstract]
Common stock warrants	4,999,883
Outstanding and issued common stock options	2,660,383	2,983,574
Unvested restricted common stock	541,225	823,603
Convertible preferred stock		15,480,195
Total	8,201,491	19,287,372

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Valuation allowance increased	$ 10.1	$ 6.2
Research and development credit carryforwards	1.3
Reduce future taxable income	1
Net operating loss	2.9
Net operating loss deferred tax assets	$ 0.6
Annual deduction limitation percentage	80.00%

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of provision for income taxes rate - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of provision for income taxes rate [Abstract]
Federal tax benefit at statutory rate	$ (6,433)	$ (6,651)
State taxes	(1,729)	(1,757)
Change in fair value of derivative	735	2,284
Change in fair value of warrant liability	(105)
Change in fair value of earnout liability	(1,948)
Non-deductible expenses	633	231
Research and development credits	(1,095)	(298)
Change in valuation allowance	10,095	6,191
Other	(153)
Provision for income taxes

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of company’s net deferred tax assets (liabilities) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Accrued expenses and other	$ 510	$ 592
Intangibles	407	369
Net operating losses	14,683	6,046
Research and development credits	1,410	315
Stock based compensation	222	179
Lease Liability	760	485
Unrealized gain/loss	13
Total deferred tax assets	18,005	7,986
Valuation allowance	(17,682)	(7,587)
Total net deferred tax assets	323	399
Deferred tax liabilities:
Right-of-use asset	(302)	(399)
Fixed assets	(21)
Total deferred tax liabilities	(323)	(399)
Net deferred tax assets

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of company’s federal and state net operating loss carryforwards $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, Amount	$ 53,071
Operating loss carryforwards, Expiration Years
States Primarily California [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, Amount	$ 45,442
Operating loss carryforwards, Expiration Years

Income Taxes (Details) - Sche_4

Income Taxes (Details) - Schedule of reconciliation of unrecognized tax benefits - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of reconciliation of unrecognized tax benefits [Abstract]
Balance at beginning of year	$ 252	$ 17
Additions based on tax positions related to current year	576	235
Balance at end of year	$ 828	$ 252

Related Parties (Details)

Related Parties (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Related Parties (Details) [Line Items]
Intellectual property rights		$ 74,000
Cash		6,000
Advisory and consulting services expenses		500,000	$ 300,000
Reduction to research and development expenses		$ 612,000	$ 488,000
Zai Lab Limited [Member]
Related Parties (Details) [Line Items]
Research project and share total expenses	$ 300,000
Reduction to research and development expenses	$ 36,000

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event [Member] $ in Millions	Jan. 01, 2022USD ($)m²
Subsequent Event (Details) [Line Items]
Rentable square feet | m²	5,611
Additional lease payments for extra space | $	$ 1.8